Critical Comparison: CymaBay Therapeutics (CBAY) & Its Competitors

CymaBay Therapeutics (NASDAQ: CBAY) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare CymaBay Therapeutics to related companies based on the strength of its risk, profitability, analyst recommendations, earnings, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a breakdown of current recommendations for CymaBay Therapeutics and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CymaBay Therapeutics 0 0 9 0 3.00
CymaBay Therapeutics Competitors 758 3015 11129 227 2.72

CymaBay Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 71.99%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.73%. Given CymaBay Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe CymaBay Therapeutics is more favorable than its competitors.

Valuation & Earnings

This table compares CymaBay Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
CymaBay Therapeutics $4.79 million -$20.29 million -7.68
CymaBay Therapeutics Competitors $260.16 million $66.28 million -6.83

CymaBay Therapeutics’ competitors have higher revenue and earnings than CymaBay Therapeutics. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares CymaBay Therapeutics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CymaBay Therapeutics N/A -425.44% -122.91%
CymaBay Therapeutics Competitors -5,494.23% -457.71% -42.78%

Risk and Volatility

CymaBay Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500. Comparatively, CymaBay Therapeutics’ competitors have a beta of 6.66, indicating that their average stock price is 566% more volatile than the S&P 500.

Insider and Institutional Ownership

25.9% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.1% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

CymaBay Therapeutics competitors beat CymaBay Therapeutics on 7 of the 12 factors compared.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply